Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 118

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 118
---
 | ​                                       |  -294 | ​ | ​    |    588 |
| All others (3)                         | ​ | ​                                       |    21 | ​ | ​    |    648 |
| Total R&D development expense          | ​ | ​                                       |   979 | ​ | ​    |  5,159 |
| R&D personnel related expenses (4)     | ​ | ​                                       |  -948 | ​ | ​    | 11,541 |
| R&D facility and depreciation expense  | ​ | ​                                       |   918 | ​ | ​    |  2,463 |
| R&D consulting expenses                | ​ | ​                                       |   670 | ​ | ​    |  2,750 |
| R&D lab supplies                       | ​ | ​                                       |   175 | ​ | ​    |  7,573 |
| R&D other expense (5)                  | ​ | ​                                       | 6,427 | ​ | ​    |  4,877 |
| Total research and development expense | ​ | $                                       | 8,221 | ​ | $    | 34,363 |

| (1) | Includes sponsored research, license and clinical trial related costs. |

| (2) | Credit for the nine months ended September 30, 2024, reflects the forgiveness of outstanding payables and accrued expenses due to the mutual termination of the license agreement and related data transfer agreement with St. Jude. Credit for the nine months ended September 30, 2023, reflects credit memos and reimbursements received from termination of services with vendors. |

| (3) | Includes costs for long-term follow-up and programs that were terminated. |

| (4) | Credit for the nine months ended September 30, 2024, primarily reflects the reversal of 2023 accrued bonus that will not be paid due to the reduction in the workforce in April 2024. |

| (5) | Includes approximately $3.2 million of expenses incurred related to the June 2024 Repurchase of Assets from uBriGene. |

Asset Impairment For the nine months ended September 30, 2024, we incurred impairment charges of $2.6 million attributable to our assessment of the recoverability of the asset group consisting of leasehold improvements and associated right-of-use asset. No impairment was recorded in the nine months ended September 30, 2023. Gain on the Sale of Property and